Amit M. Oza

Also affiliated with Princess Margaret Cancer Centre

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 13 papers. Top paper: “MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum”.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Journal of Clinical Oncology(2020)10.1200/jco.20.01164

N/A

4.6DataRank · unranked

153 citations

Rachel N. Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero +25 more

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0621

N/A

0.949DataRank · unranked

22 citations

Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza +25 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005919

N/A

0.812DataRank · unranked

25 citations

Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley +16 more

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0065

N/A

0.500DataRank · unranked

27 citations

Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer +12 more

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

The Lancet Oncology(2022)10.1016/s1470-2045(22)00139-5

N/A

0DataRank · unranked

142 citations

Antonio González-Martı́n, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Jean‐Emmanuel Kurtz +73 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more

A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5514

N/A

0DataRank · unranked

22 citations

Husam Alqaisi, David E. Cohn, Jing‐Yi Chern, Linda Duska, Andrea Jewell +15 more

Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5541

N/A

0DataRank · unranked

3 citations

Sandra A. Mitchell, Tyler Pittman, Lisa Wang, Valerie Bowering, Nisan Kavak +9 more

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

medRxiv(2023)10.1101/2023.03.20.23287465

N/A

0DataRank · unranked

9 citations

John J. Krais, Cassandra J. Vandenberg, Yifan Wang, Pooja Patel, Kathy Q. Cai +30 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0094

N/A

0DataRank · unranked

19 citations

Sajid A. Marhon, Naïri Tchrakian, Anjelica Hodgson, Helen Loo Yau, Isabela M. Gonzaga +43 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more